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Abstract
Background: Early diagnosis and treatment of prediabetes and type 2 diabetes mellitus (T2DM) can prevent future
health problems, yet many individuals with these conditions are undiagnosed. This could be due, in part, to primary
care physicians’ (PCP) screening practices, about which little is known. The objectives of this study were to identify
factors that influence PCPs’ decisions to screen patients for T2DM and to characterize their interpretation and
communication of screening test results to patients.
Methods: We conducted semi-structured chart-stimulated recall interviews with 20 University of Michigan Health
System (UMHS) primary care physicians. PCPs were asked about their recent decisions to screen or not screen 134
purposively sampled non-diabetic patients who met American Diabetes Association criteria for screening for T2DM.
Interviews were audio-recorded, transcribed, and analyzed using qualitative directed content analysis. Data on patient
demographic characteristics and comorbidities were abstracted from the electronic health record.
Results: The most common reasons PCPs gave for not screening 63 patients for T2DM were knowledge of a
previously normal screening test (49%) and a visit for reasons other than a health maintenance examination
(48%). The most common reasons PCPs gave for screening 71 patients for T2DM were knowledge of a previously
abnormal screening test (49%), and patients’ weight (42%) and age (38%). PCPs correctly interpreted 89% of screening
test results and communicated 95% of test results to patients. Among 24 patients found to have prediabetes, PCPs
usually (58%) recommended weight loss and increased physical activity but never recommended participation in a
Diabetes Prevention Program or use of metformin.
Conclusions: Previous screening test results, visit types, and patients’ weight and age influenced PCPs’ decisions
to screen for T2DM. When patients were screened, test results were generally correctly interpreted and consistently
communicated. Recommendations to patients with prediabetes could better reflect evidence-based strategies to
prevent T2DM.
Keywords: Type 2 diabetes mellitus, Prediabetes, Diabetes prevention, Primary care, Preventive care, Communication,
lifestyle counseling
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Background
Type 2 diabetes mellitus (T2DM) affects 25.1 million US
adults and is a major cause of cardiovascular disease,
kidney disease, blindness, and lower extremity amputa-
tion [1]. An additional 86 million individuals – one third
of the US adult population – are estimated to have pre-
diabetes [1], which if left untreated will result in 5–10%
of these individuals progressing to T2DM each year [2].
Fortunately, T2DM and its complications can often be
prevented through early detection and treatment of
T2DM [3] and prediabetes [4, 5]. Several national initia-
tives are now aiming to identify more individuals with
these conditions and connect them to evidence-based
treatments. For example, in 2015 the US Centers for Dis-
ease Control and Prevention (CDC) and the American
Medical Association (AMA) launched “Prevent Diabetes
STAT: Screen/ Test / Act Today,” a joint initiative that en-
courages diabetes prevention through screening for
T2DM and referral to a Diabetes Prevention Program
(DPP) [6]. Also in 2015, the United States Preventive
Services Task Force (USPSTF) updated its recommenda-
tion for screening of adults for T2DM to include behav-
ioral counseling interventions for those with abnormal
results [7]. Most recently, the Centers for Medicare and
Medicaid Services announced Medicare would cover the
DPP for beneficiaries with prediabetes [8], joining the
growing numbers of private insurers already doing so [9].
The promise of these national initiatives to improve
population health hinges on the early identification and
management of T2DM and prediabetes, which often be-
gins in primary care practices through tests to screen for
T2DM and communication of these test results to
patients. Therefore, decisions primary care physicians
make about whom to screen for T2DM, interpretation
of screening test results, and communication of these
results to patients can have important implications. For
example, if clinicians do not accurately perceive risk
factors for T2DM or if they incorrectly interpret screen-
ing test results, they may fail to identify at-risk patients.
Further, clinicians may not communicate T2DM screen-
ing test results to patients or they may not provide
evidence-based treatment recommendations, which can
affect patients’ perceptions of risk and their decisions
about preventive behaviors [10]. If these deficiencies are
widespread, they could help explain why more than 80
million individuals with T2DM and prediabetes are un-
aware they have these conditions [11].
Despite the population health implications of primary
care physicians’ T2DM screening practices, little is
known about how primary care physicians decide which
patients to screen for T2DM, what screening tests they
choose, how they interpret screening test results, and
what they communicate to patients about these results.
The objective of our study was to identify factors that
influence primary care physicians’ decisions to screen
patients for T2DM and to characterize primary care
physicians’ interpretation and communication of screen-
ing test results to patients.
Methods
Study design
Our team, which consisted of 3 primary care physician
health services researchers, 1 fulltime primary care clin-
ician, and 2 preclinical medical students, invited Internal
Medicine physicians (n = 50), Family Medicine physi-
cians (n = 39), nurse practitioners (n = 2), and physician
assistants (n = 5) from 14 UMHS primary care practices
to participate in a study about T2DM screening prac-
tices. We excluded trainees and clinicians with less than
0.5 full time equivalents devoted to outpatient clinical
practice. Study invitation letters were sent by email, and
informed providers that the primary aim of this study
was to explore the factors that influence providers’ deci-
sions to screen for T2DM.
Among clinicians who consented to study participation
we conducted chart-stimulated recall (CSR) interviews, a
methodology used to assess clinical decision-making pro-
cesses [12, 13]. During CSR interviews, a clinician uses his
or her own documentation to answer questions and ex-
plain the rationale for specific clinical decisions. A signifi-
cant strength of this approach – which has been used to
examine physician decisions about screening for colorectal
cancer [14] and screening for prostate cancer [15] – is that
it examines a physician’s own recent clinical decisions,
which could provide more valid data on their clinical deci-
sion making than assessments of how they might respond
to hypothetical clinical scenarios.
Sample
Twenty-five physicians responded to our recruitment e-
mail and agreed to participate in our study. We planned
to conduct a minimum of 20 interviews with additional
interviews to be conducted only if data saturation was not
achieved at this point. Prior to each CSR interview, one
investigator (DH) reviewed in the electronic health record
(EHR) each physician’s clinical encounters from the previ-
ous 2 weeks to identify visits for non-diabetic patients
45 years of age and older who were candidates for screen-
ing for T2DM at their visit and thus eligible for inclusion
in the CSR interviews. We focused on patients 45 years of
age and older for 2 reasons. First, the American Diabetes
Association (ADA) recommends screening all individuals
over the age of 45 for T2DM regardless of other risk
factors; therefore an age-based focus allowed us to easily
identify patients for whom the ADA recommends periodic
T2DM screening. Second, this age-based criterion was
more feasible to implement in the context of the EHR
than other more detailed criteria for which the ADA
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recommends screening for T2DM, such as being less than
45 years of age and overweight with at least one additional
risk factor for T2DM [16].
While both the ADA and the USPSTF recommend
routine screening for T2DM among at-risk individuals,
we used the ADA’s screening criteria because at the time
of our interviews they were broader than the 2008
USPSTF criteria [17]. The USPSTF has since issued re-
vised screening guidelines (disseminated in October
2015), but these were released after completion of all
CSR interviews. We did not sample patients who had
already been screened for T2DM within the previous
year, as most non-diabetic patients do not need to be
screened more than annually [16] and this study was not
designed to explore reasons for over-screening.
To facilitate discussion of the range of factors that in-
fluence physicians’ decisions to screen for T2DM, we se-
lected in approximately equal numbers encounters in
which patients appeared (using the available information
in the EHR) to have been screened for T2DM or not
screened for T2DM. We classified the following as
screening tests for T2DM, based on the ADA guidelines:
hemoglobin A1c (HbA1c) tests, oral glucose tolerance
tests (OGTTs), and fasting blood glucose (FBG) tests
[16]. Because blood glucose tests at our institution are
not routinely labeled as “fasting,” we classified blood glu-
cose tests (drawn either in isolation or as part of a meta-
bolic panel) as being fasting if they were obtained before
11 a.m. or drawn at the same time as a lipid panel that
had been labeled in the EHR as fasting.
We also sampled in approximately equal numbers
encounters in which patients were seen for either
health maintenance examinations (HMEs) or return
visits (RVs). We focused on both HMEs and RVs be-
cause there is debate about the utility of annual HMEs
[18–20] and physicians have been encouraged to con-
sider providing opportunistic preventive screenings at
non-HME visits [21–23]. We excluded urgent care
visits because in our institution these are typically fo-
cused, single-problem visits in which patients are com-
monly seen by clinicians other than their own primary
care clinician.
Using this approach, for each clinician we aimed to se-
lect 12 encounters (i.e., roughly 3 each for HMEs with
screening, HMEs without screening, RVs with screening,
and RVs without screening) from the previous 2 weeks
to potentially be discussed during the CSR interview. A
goal of 12 encounters for each physician provided the
opportunity to skip a particular encounter during the
interview in the event that the clinician did not recall
the encounter, while still permitting discussion of at least
6 separate patient encounters which has previously been
shown sufficient to yield a valid and reliable assessment
of practice patterns [24].
Interviews were conducted by trained preclinical med-
ical students (DN, EM) and lasted approximately 30 min
in duration. During the CSR interviews, physicians were
first asked whether they screened each patient for
T2DM and what factors influenced this decision. Our
questions about reasons for the physician’s decision were
guided by whether the physician stated they had or had
not screened the patient for T2DM, rather than how the
patient had been classified in our purposive sampling.
For example, if it appeared from the EHR that the phys-
ician had screened the patient for T2DM, but the phys-
ician stated that they had not screened the patient for
T2DM, then the physician was asked why they had not
screened the patient for T2DM. Conversely, if a patient
had been sampled as having not been screened (e.g., be-
cause they had a random glucose), but the physician said
they had screened the patient for T2DM, we asked the
physician why they screened the patient (even though
the test chosen was not an ADA-recommended test).
This approach allowed us to focus on physicians’ deci-
sion making processes irrespective of the outcome of
that process.
When a screening test result was available for review
(i.e., there was a lab result for a screening test that had
been ordered at that visit), physicians were asked how they
interpreted the result, whether and how they communi-
cated the result to the patient, and what they communi-
cated to the patient about the result. Following the CSR
interview, physicians were also asked general questions
regarding barriers to T2DM screening. Physicians had ac-
cess to their EHR documentation during the interview.
The interview guide was derived from previous CSR stud-
ies [14, 15] and is provided in the Additional file 1.
For each interview, physicians received a $50 gift card.
The study was approved by the Institutional Review
Board at the University of Michigan Medical School.
Analysis
All interviews were audio-recorded and transcribed
verbatim. Three members of the research team (DH, DN, JK)
independently reviewed a subset of transcripts. The
transcripts were de-identified prior to data analysis to
minimize the potential for biased interpretation of the
data. Codes and definitions were generated during consensus
conferences using directed content analysis [25].
Specifically, initial codes were created to reflect the
main topics in the interview guide (e.g. decision to screen or
not screen patients for T2DM), and additional codes were
subsequently generated to reflect the patterns and themes
that emerged from the data [26]. Once the coding scheme
was established, two investigators (DH, DN) independently
coded each transcript. These investigators then met to
review their coding and resolve all differences. Few new
themes emerged after coding 12 transcripts and no new
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themes emerged after coding 16 transcripts. Given that we
reached data saturation [27, 28], we did not conduct add-
itional interviews following the 20 interviews. All transcripts
were coded in Dedoose, a software program for qualitative
analysis.
The following data were abstracted from the EHR for
each patient after the interviews were completed: age; sex;
race; ethnicity; BMI; risk factors for T2DM documented
in the patient’s problem list such as hypertension, hyper-
lipidemia, cardiovascular disease, prediabetes, history of
gestational diabetes or polycystic ovarian disease.
Results
Twenty primary care physicians (14 Internal Medicine
and 6 Family Medicine) across 10 clinic sites participated
in the study. There were no nurse practitioners or phys-
ician assistants who responded to our invitation.
These 20 physicians discussed a total of 156 patients
who met our study inclusion criteria (mean 7.8 patients
per physician) during the CSR interviews we conducted
between January 2015 and July 2015. We then limited
our analyses to the 63 patients who physicians stated
they did not screen for T2DM and the 71 patients who
physicians stated they screened for T2DM. We excluded
22 patients from our analyses because at the sampling
stage they appeared to have been screened for T2DM with
a blood glucose drawn prior to 11 a.m., but during the
interview physicians indicated they did not screen the pa-
tient for T2DM and rather had ordered the blood glucose
as part of an electrolyte panel to monitor kidney function.
A total of 134 patients were included in our analysis.
In general, the patients who were screened for T2DM
were had a higher BMI and a greater prevalence of pre-
diabetes compared to patients who were not screened.
Additionally, screening was more likely to occur during
HMEs than RVs. Patient characteristics, stratified accord-
ing to whether they had been screened for T2DM during
the discussed encounter, are summarized in Table 1.
Screening decisions
For the 63 patients who were not screened for T2DM, the
most common reasons for not screening that physicians
cited were knowledge of a previous normal screening test
(49%) and the visit being for a reason other than a health
maintenance examination (48%). Clinicians frequently
cited more than one reason for not screening, and add-
itional reasons are shown in Table 2.
For the 71 patients who were screened for T2DM, the
most common reasons for screening that physicians
cited were knowledge of a previously abnormal screen-
ing test for T2DM (49%), the patient being overweight
or obese (42%), and patient age (38%). Two physicians
specifically mentioned age ≥ 45 years as a screening cri-
terion; others referenced the patient’s actual age (e.g.
“she is 60 years old”) or noted that “the risk of diabetes
goes up as we get older.” Clinicians often cited multiple
reasons for screening, and these additional reasons are
shown in Table 3.
Among the 71 patients who were screened for T2DM,
the most commonly ordered screening tests were a
laboratory HbA1c (n = 29, 40.8%) and a fasting blood
glucose (n = 23, 32.4%). Four patients (5%) were screened
with a point-of-care HbA1c, and 8 patients were
screened with a random blood glucose (i.e., a blood
glucose drawn after 11 a.m.). Seven patients (9.9%) had
more than one screening test ordered (i.e., both a fasting
blood glucose and an HbA1c). No physician ordered an
OGTT to screen for T2DM. Physicians reported order-
ing an HbA1c test for reasons such as: “it is more famil-
iar and comfortable,” “it is a little more reliable,”
“patients don’t need to be fasting” and “it gives a better
Table 1 Patient characteristics (n = 134)
Characteristics Screened for
T2DM (n = 71)
Not screened for
T2DM (n = 63)
p-valuea
Mean (SD) or n (%)
Age (years) 57.5 (9.6) 61.4 (12.2) 0.041
BMI (kg/m2) 31.4 (6.6) 28.6 (5.7) 0.012
Female 34 (47.9) 39 (61.9) 0.10
Raceb
White 57 (80.3) 57 (90.5) 0.23
Black 7 (9.9) 2 (3.2)
Asian 3 (4.2) 1 (1.6)





48 (67.6) 19 (30.2) <0.001
Return visit 23 (32.4) 44 (69.8)
Comorbiditiese
Hyperlipidemia 38 (53.2) 25 (39.7) 0.11
Hypertension 28 (39.4) 21 (33.3) 0.46
Cardiovascular
disease
3 (4.2) 3 (4.8) 0.88
Prediabetesf 15 (21.1) 2 (3.2) 0.002
ap-values were derived using logistic regression for continuous variables and
Chi-squared test for categorical variables
bRace was listed in the EHR as “other” or “not reported” for 6 patients (4.5%)
cEthnicity was listed in the EHR as “unknown” or “not reported” for 12
patients (9.0%)
d“Return visits” refer to problem-focused visits that range from 15 to 30 min in
duration. “Health maintenance examinations” refer to prevention-focused visits
that range from 40 to 45 min in duration
eThe list of co-morbidities was selected based on the American Diabetes
Association’s criteria for screening for type 2 diabetes mellitus. There were
no patients in our sample who had a documented history of 2 other ADA
criteria for screening: polycystic ovarian syndrome and gestational diabetes mellitus
fPatients were classified as having prediabetes if they had one or more of the
following diagnoses listed on their EHR problem list: prediabetes, impaired
glucose tolerance, impaired fasting glucose, or borderline diabetes
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[overall] picture.” Physicians ordered a fasting blood glu-
cose – either in isolation or as part of a metabolic panel
– if the patient had already been fasting for another test
(e.g., a fasting lipid panel) or if the physician wanted to
concurrently evaluate other components of the meta-
bolic panel (e.g., electrolytes or renal function).
Interpretation of screening test results
Of the 71 patients for whom screening tests for T2DM
were ordered, 50 had screening test results available in
the EHR for review at the time of the interview. Based
on the ADA guidelines,[29] 24 patients had screening
test results that showed prediabetes, and 26 patients had
screening test results that were normal. None of the
sampled patients were found to have a new diagnosis of
T2DM. Physicians discussed 47 of the 50 available test
results, and of these correctly classified the majority
(42, 89%) of the screening test results.
Communication of screening test results
Physicians communicated 95% of screening test results
to patients. Most communications occurred by mailed
letter or secure electronic messaging through the health
system’s patient portal (69%). Communication occurred
by phone when either the screening test or another
laboratory study was abnormal (16%); such telephone
communications were always performed by a nurse.
Communication occurred during an office visit only if
the patient had laboratory tests performed prior to the
encounter (15%).
Among patients found to have prediabetes, the con-
tent of communications focused mostly on diet and ex-
ercise, often with offers of referral to a nutritionist. For
example, one physician stated, “I told her…diet and exer-
cise would be the key. [We] can also offer referral to our
nutritionist for pre-diabetes counseling, if she would
like.” In many cases, physicians’ recommendations to
patients were general and lacked specific goals or tar-
gets. An example of this was a physician who recom-
mended, “just to continue with, what we call…lifestyle
modifications. You know, a little bit of exercise, healthy
diet, stuff like that.” Some physicians minimized the sig-
nificance of screening test results if they were at the
lower end of the prediabetic range. For example, one
physician said, “[The blood glucose] is slightly high at
101. What I told [him] is that he is just out normal
range, but not in a concerning…urgent way, and that
we’ll talk about it in his next visit.” Another said, “[The
HbA1c] is stable from a year ago at 6.2%, which I feel is
consistent with pre-diabetes and puts her at a high risk
of developing diabetes…[I told her] that the lab looks
stable…I kept it very short and sweet. I probably could
have said something more about lifestyle.”
Communications to patients with prediabetes never
included specific, evidence-based treatment recommen-
dations such as DPP participation or pharmacotherapy
with metformin [30]. One physician said that “we talked
about the diabetes prevention trial, and we set 150 min
of exercise for her goal [per] week,” but she did not spe-
cifically recommend or refer the patient to a DPP. None
of the physicians started metformin for patients whose
test results were in the prediabetic range, although one
mentioned that a patient with prediabetes was already
using metformin and a few acknowledged that metfor-
min might be an option for such patients. One physician
said, “I know there is some data talking about using met-
formin early on people like this. I don’t like to add more
medications than I have [to]. So I don’t typically do that
until the A1C starts to get up to closer to 6.5.”
Table 2 Physician-identified reasons for not screening for type
2 diabetes mellitus (n = 63)
Reasons n (%)a
Previously normal T2DM screening test result(s) 31 (49.2)
Return visit 30 (47.6)
Normal weight 6 (9.5)
Future health maintenance examination 4 (6.4)
Normal blood pressure 2 (3.2)
Did not believe screening indicated based on guidelines 2 (3.2)
Younger age 2 (3.2)
Otherb 12 (19.1)
aNumber of times code occurred and frequency of occurrence among the 63
patients who were not screened. Codes were not mutually exclusive and
therefore the percentages sum to more than 100
bIncludes physician not being the patient’s primary care physician; patient reported
recent normal labs obtained elsewhere; patient preference to avoid a blood draw;
patient enrolled in hospice
Table 3 Physician-identified reasons to screen for type 2 diabetes
mellitus (n = 71)
Reasons n (%)a
Previously abnormal screening test result(s) 35 (49.3)
Overweight or obesity 30 (42.3)
“Older age” 27 (38.0)
Hypertension 18 (25.4)
Hyperlipidemia 11 (15.5)
Health maintenance examination 8 (11.3)
Family history of T2DM 6 (8.5)
Sedentary lifestyle 4 (5.6)
History of cardiovascular disease 3 (4.2)
Race/ethnicity 3 (4.2)
Tobacco use 3 (4.2)
aNumber of interviews in which the theme emerged and the frequency of
occurrence using total number patients who physicians intended to screen
(71) in the denominator
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Discussion
Through CSR interviews among primary care physicians
of a large academic medical center we found that screen-
ing for T2DM was appropriately targeted to patients
with major risk factors for T2DM, including a history of
prediabetes, older age, and being overweight or obese.
The main reasons for not screening for T2DM included
physicians’ knowledge of previously normal results of a
screening test for T2DM and clinical encounters for rea-
sons other than an HME. While physicians usually inter-
preted screening results correctly and consistently
communicated these results to patients, they never rec-
ommended evidence-based treatments to patients with
prediabetes, such as Diabetes Prevention Program par-
ticipation or use of metformin.
One contributor to high rates of undiagnosed predia-
betes and T2DM may be screening among only patients
with certain risk factors. Consistent with prior studies
[31], physicians in our study targeted screening to indi-
viduals with certain major risk factors for T2DM such as
obesity or a previously abnormal screening test result.
However, our findings suggest that physicians may miss
opportunities to screen older individuals who lack other
risk factors for T2DM. Specifically, although “older age”
was cited as reason for screening in over one-third of
the discussed encounters, all of the patients discussed
during the CSR interviews were old enough to meet
ADA criteria for screening for T2DM. Further, in our
sample the mean age was actually lower among patients
who were screened for T2DM compared with patients
who were not screened (58 years versus 61 years). One
practical strategy to help clinicians consistently identify
patients with major risk factors for T2DM would be to
integrate age-based clinical reminders into the EHRs, an
approach that has been shown to improve targeting of
other types of clinical preventive services [32, 33].
A clinical encounter for a reason other than an HME
was a common reason why physicians did not screen for
T2DM, which suggests additional missed opportunities
to screen at-risk patients for T2DM. While some physi-
cians mentioned intentionally deferring screening to fu-
ture HMEs, others felt they simply did not have the time
to address preventive health issues in the context of
problem-focused encounters. Primary care clinicians have
been increasingly encouraged to perform opportunistic
screenings during problem-focused and urgent care en-
counters [23, 28], and practice innovations could offer op-
portunities for other members of primary care teams to
share responsibility for screening patients for T2DM when
they seek primary care for a broader range of reasons [34].
While the primary care physicians we interviewed nearly
always correctly interpreted results of screening tests for
T2DM, their responses to these screening tests suggest
many patients may not be receiving evidence-based
preventive recommendations and treatments. Specifically,
physicians never referred patients with prediabetes to a
DPP or initiated treatment with metformin. This is con-
sistent with prior studies, which show that physicians
often fail to respond to abnormal screening test results
[27, 35]. For example, one previous study found less than
1% of patients with prediabetes were prescribed metfor-
min, and only 5% were referred to or attended health edu-
cation, wellness, or lifestyle programs [35, 36]. Educational
initiatives to increase physician awareness of the benefits
of the DPP and metformin could be considered. However,
because primary care physicians often report being over-
burdened with preventive health tasks [37] an alternative
strategy might be to reflexively target patients with predia-
betes for education about strategies to prevent T2DM.
Limitations
First, we conducted our study in a single academic center
and our findings may not generalize to all clinical environ-
ments. Second, it is possible that physicians with a particu-
lar interest in screening for T2DM may have been more
likely to participate in the study, and there were no nurse
practitioners or physician assistants who chose to partici-
pate. Third, none of the patients discussed in the CSR inter-
views were found to have T2DM through screening, thus
limiting our insight into how physicians interpret and re-
spond to such results. Fourth, physicians’ responses could
have been influenced by recall or social desirability biases,
though physician use of the EHR during interviews and our
inquiries about recent visits by preclinical medical students
aimed to mitigate the potential for such biases. Further, al-
though physician access to the EHR at the time of the inter-
view was intended to prompt recall of the encounter, it is
possible that some physicians may have used EHR data to
justify their decisions to screen or not screen a patient for
T2DM. Finally, the USPSTF issued an updated recommen-
dation for screening for T2DM following our study period,
which could lead to changes in physician screening prac-
tices that we could not capture during this study.
Conclusions
Our study provides new insight into T2DM screening
practices among primary care physicians. We identified
factors that may contribute to high rates of undiagnosed
T2DM and prediabetes and thus could limit the impact of
recent national initiatives aimed at reducing the public
health burden of T2DM and its complications. These fac-
tors could be addressed through systems-based strategies
to increase the early identification and evidence-based
treatment of patients with abnormal screening tests for
T2DM. More research is needed to determine whether
such strategies can increase the early identification of at-
risk patients and better connect these patients with
evidence-based treatments.
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